BRPI0713749B8 - formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea - Google Patents

formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea

Info

Publication number
BRPI0713749B8
BRPI0713749B8 BRPI0713749A BRPI0713749A BRPI0713749B8 BR PI0713749 B8 BRPI0713749 B8 BR PI0713749B8 BR PI0713749 A BRPI0713749 A BR PI0713749A BR PI0713749 A BRPI0713749 A BR PI0713749A BR PI0713749 B8 BRPI0713749 B8 BR PI0713749B8
Authority
BR
Brazil
Prior art keywords
liquid
growth factor
vascular endothelial
endothelial growth
ophthalmic formulations
Prior art date
Application number
BRPI0713749A
Other languages
English (en)
Portuguese (pt)
Inventor
Dix Daniel
Furfine Eric
Frye Kelly
S Graham Kenneth
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713749(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0713749A2 publication Critical patent/BRPI0713749A2/pt
Publication of BRPI0713749B1 publication Critical patent/BRPI0713749B1/pt
Publication of BRPI0713749B8 publication Critical patent/BRPI0713749B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BRPI0713749A 2006-06-16 2007-06-14 formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea BRPI0713749B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81448406P 2006-06-16 2006-06-16
US60/814484 2006-06-16
PCT/US2007/014085 WO2007149334A2 (en) 2006-06-16 2007-06-14 Vegf antagonist formulations suitable for intravitreal administration

Publications (3)

Publication Number Publication Date
BRPI0713749A2 BRPI0713749A2 (pt) 2012-11-06
BRPI0713749B1 BRPI0713749B1 (pt) 2021-03-02
BRPI0713749B8 true BRPI0713749B8 (pt) 2021-05-25

Family

ID=38834013

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713749A BRPI0713749B8 (pt) 2006-06-16 2007-06-14 formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea

Country Status (22)

Country Link
US (16) US7608261B2 (enExample)
EP (4) EP2944306B1 (enExample)
JP (2) JP5216002B2 (enExample)
KR (1) KR101406811B1 (enExample)
CN (2) CN104434770A (enExample)
AU (1) AU2007261536C1 (enExample)
BR (1) BRPI0713749B8 (enExample)
CA (1) CA2654510C (enExample)
CY (2) CY1114244T1 (enExample)
DK (2) DK2944306T3 (enExample)
ES (2) ES2861898T3 (enExample)
HK (1) HK1204580A1 (enExample)
HU (2) HUE053612T2 (enExample)
IL (1) IL195788A (enExample)
LT (1) LT2944306T (enExample)
MX (1) MX2008016124A (enExample)
PL (2) PL2364691T3 (enExample)
PT (2) PT2364691E (enExample)
RU (1) RU2432155C3 (enExample)
SI (2) SI2364691T1 (enExample)
WO (1) WO2007149334A2 (enExample)
ZA (1) ZA200809827B (enExample)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ617083A (en) * 2003-08-27 2015-04-24 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
CN104434770A (zh) 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
PL2152118T3 (pl) 2007-01-18 2011-09-30 Eveready Battery Inc Zespół do golenia zawierający ogniwo generujące gaz
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
PE20140372A1 (es) 2011-01-28 2014-03-24 Sanofi Sa Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
ES2909777T3 (es) 2011-11-18 2022-05-10 Regeneron Pharma Formulación de liberación prolongada que comprende micropartículas para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares
CN107115294B (zh) * 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
CN104169299B (zh) 2012-01-23 2018-06-05 瑞泽恩制药公司 含抗Ang-2 抗体的稳定化制剂
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
EA201492289A1 (ru) * 2012-06-01 2015-05-29 Офтотек Корпорейшн Композиции, содержащие аптамер против pdgf и антагонист vegf
CN104780906A (zh) 2012-06-01 2015-07-15 诺华股份有限公司 注射器
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2013100360B4 (en) * 2012-07-03 2013-05-16 Novartis Ag Device
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
US8922746B2 (en) 2012-08-06 2014-12-30 Shenzhen China Star Optoelectronics Technology Co., Ltd Liquid crystal injection device and liquid crystal container thereof
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
JP2016523847A (ja) 2013-06-07 2016-08-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｃｓｋ９のインヒビターの投与によりアテローム性動脈硬化を阻害する方法
KR20220061248A (ko) 2013-07-12 2022-05-12 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CN103622961B (zh) * 2013-09-06 2016-03-02 武汉光谷百桥国际生物科技有限公司 一种非肽类缓激肽b2受体激动剂在促进毛发生长方面的应用
CN118105482A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
WO2015071348A1 (en) * 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011256A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH)
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN107206080B (zh) 2015-01-28 2022-07-08 辉瑞公司 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
IL258570B2 (en) * 2015-10-16 2024-07-01 Regeneron Pharma Stable protein preparations
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
WO2017087871A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
AU2016369557B2 (en) * 2015-12-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
AU2017213103B2 (en) * 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
MY195228A (en) 2016-07-29 2023-01-11 Regeneron Pharma Assembly Line with Integrated Electronic Visual Inspection
JP2019529350A (ja) 2016-08-16 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 混合物から個々の抗体を定量する方法
WO2018063963A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
BR112019006689A2 (pt) 2016-10-25 2019-06-25 Regeneron Pharma métodos e sistemas para análise de dados de cromatografia
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
JP7161494B2 (ja) 2017-05-06 2022-10-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019055902A1 (en) 2017-09-18 2019-03-21 Amgen Inc. FUSION PROTEIN FORMULATIONS VEGFR-FC
KR102798879B1 (ko) 2017-09-19 2025-04-30 리제너론 파아마슈티컬스, 인크. 입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물
US12156900B2 (en) 2017-11-17 2024-12-03 Amgen Inc. VEGFR-Fc fusion protein formulations
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
ES2927049T3 (es) 2017-11-30 2022-11-02 Regeneron Pharma Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos
WO2019118187A1 (en) * 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
MA51162A (fr) 2017-12-15 2020-10-21 Apellis Pharmaceuticals Inc Schémas posologiques et compositions et procédés associés
JP7692699B2 (ja) * 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
DK3743091T3 (da) 2018-01-26 2025-01-06 Univ California Fremgangsmåder og sammensætninger til behandling af angiogene lidelser under anvendelse af anti-vegf-midler
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
JP2021521107A (ja) * 2018-04-05 2021-08-26 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ｔｅｒｔ−ブタノールレベルを低下させた医薬組成物
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
PT4364724T (pt) * 2018-05-10 2025-12-16 Regeneron Pharma Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
WO2020087003A1 (en) 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
NZ785118A (en) * 2019-08-01 2025-09-26 Gennova Biopharmaceuticals Ltd Opthalmic composition of bevacizumab
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CA3150482A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
EP3906303A1 (en) 2019-12-06 2021-11-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
BR112022022288A2 (pt) 2020-05-11 2022-12-20 Regeneron Pharma "métodos para purificar um peptídeo ou proteína de uma amostra e para produzir uma preparação compreendendo uma proteína de interesse e uma quantidade reduzida de partículas virais de uma amostra com a proteína de interesse e uma partícula viral infecciosa
KR102690020B1 (ko) 2020-07-24 2024-08-01 (주)팬젠 안과용 액상 조성물
US20230312683A1 (en) * 2020-07-31 2023-10-05 Celltrion Inc. Stable pharmaceutical preparation
CN112245569B (zh) * 2020-11-18 2024-05-28 通化东宝药业股份有限公司 一种稳定的阿柏西普制剂及其制备方法
KR102720956B1 (ko) * 2020-12-15 2024-10-24 삼천당제약주식회사 안과용 제형을 포함하는 시린지
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
WO2023153535A1 (ko) * 2022-02-09 2023-08-17 삼천당제약주식회사 안과용 제형을 포함하는 시린지
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1046492A (en) 1907-11-14 1912-12-10 Walter Chisholm Ranson Flushing apparatus.
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
MX9306133A (es) 1992-10-02 1994-04-29 Kabi Pharmacia Ab Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK2275119T3 (da) 1995-07-27 2013-11-11 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
CA2370246C (en) 1999-04-16 2017-03-21 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6777429B1 (en) 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003004098A1 (en) 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
US20030171320A1 (en) * 2001-11-09 2003-09-11 Guyer David R. Methods for treating ocular neovascular diseases
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
DK1608685T3 (da) 2003-03-28 2007-06-11 Regeneron Pharma VEGF antagonister til behandlingen af diabetes
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
RS20181002A1 (sr) 2003-05-30 2018-12-31 Genentech Inc Tretman sa anti-vegf antitelima
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (en) 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
NZ617083A (en) 2003-08-27 2015-04-24 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
WO2005102303A2 (en) 2004-04-21 2005-11-03 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
WO2006009809A2 (en) 2004-06-18 2006-01-26 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006015297A2 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
CN101014617B (zh) 2004-08-17 2011-03-30 瑞泽恩制药公司 Il-1拮抗剂制剂
WO2006043965A1 (en) 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2006047325A1 (en) * 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN104434770A (zh) 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US20090202855A1 (en) 2008-01-09 2009-08-13 Saxton David M Porous sliding bearing and method of construction thereof
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN107115294B (zh) 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
ES2648809T3 (es) 2014-01-25 2018-01-08 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína de fusión que inhibe la angiogénesis o el crecimiento y uso de esta
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
JP7692699B2 (ja) 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物

Also Published As

Publication number Publication date
US20120087929A1 (en) 2012-04-12
US20200017572A1 (en) 2020-01-16
US20070293432A1 (en) 2007-12-20
CY1124265T1 (el) 2021-10-29
US11732024B2 (en) 2023-08-22
US20140323983A1 (en) 2014-10-30
ZA200809827B (en) 2011-10-26
US9914763B2 (en) 2018-03-13
EP2364691A1 (en) 2011-09-14
RU2432155C3 (ru) 2017-11-17
US9340594B2 (en) 2016-05-17
US20250042972A1 (en) 2025-02-06
CN104434770A (zh) 2015-03-25
JP5597271B2 (ja) 2014-10-01
ES2406764T3 (es) 2013-06-10
PT2944306T (pt) 2021-02-15
DK2944306T3 (da) 2021-03-08
CN101478949A (zh) 2009-07-08
WO2007149334A2 (en) 2007-12-27
US12331099B2 (en) 2025-06-17
JP2009540001A (ja) 2009-11-19
KR20090018807A (ko) 2009-02-23
US7608261B2 (en) 2009-10-27
US8481046B2 (en) 2013-07-09
IL195788A (en) 2014-02-27
BRPI0713749B1 (pt) 2021-03-02
EP2944306A1 (en) 2015-11-18
KR101406811B1 (ko) 2014-06-12
US9580489B2 (en) 2017-02-28
US20130274189A1 (en) 2013-10-17
AU2007261536C1 (en) 2025-08-14
RU2009101226A (ru) 2010-07-27
US20160244505A1 (en) 2016-08-25
US20110257601A1 (en) 2011-10-20
RU2432155C2 (ru) 2011-10-27
MX2008016124A (es) 2009-01-20
SI2364691T1 (sl) 2013-08-30
HUE053612T2 (hu) 2021-07-28
JP5216002B2 (ja) 2013-06-19
US20230374108A1 (en) 2023-11-23
US20200131246A1 (en) 2020-04-30
CA2654510A1 (en) 2007-12-27
HK1204580A1 (en) 2015-11-27
US20190031735A1 (en) 2019-01-31
LT2944306T (lt) 2021-02-25
US10400025B2 (en) 2019-09-03
ES2861898T3 (es) 2021-10-06
US8802107B2 (en) 2014-08-12
JP2013151514A (ja) 2013-08-08
KR101406811B9 (ko) 2025-09-25
EP3753548A1 (en) 2020-12-23
US20160213608A1 (en) 2016-07-28
WO2007149334A3 (en) 2008-05-29
CY1114244T1 (el) 2016-08-31
PT2364691E (pt) 2013-05-15
CA2654510C (en) 2015-03-17
BRPI0713749A2 (pt) 2012-11-06
EP2029103A2 (en) 2009-03-04
US20100075903A1 (en) 2010-03-25
DK2364691T3 (da) 2013-07-01
US20210340220A1 (en) 2021-11-04
IL195788A0 (en) 2009-09-01
HUE018715T2 (hu) 2024-10-28
US10464992B2 (en) 2019-11-05
AU2007261536A1 (en) 2007-12-27
PL2944306T3 (pl) 2021-07-12
US11084865B2 (en) 2021-08-10
EP2364691B1 (en) 2013-04-24
US20250257118A1 (en) 2025-08-14
PL2364691T3 (pl) 2013-08-30
SI2944306T1 (sl) 2021-04-30
AU2007261536B2 (en) 2012-02-16
US11066458B2 (en) 2021-07-20
US8092803B2 (en) 2012-01-10
EP2944306B1 (en) 2021-01-27
US7807164B2 (en) 2010-10-05
US20180155408A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
BRPI0713749B8 (pt) formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea
HRP20190918T1 (hr) Ciljani terapeutski fuzijski proteini lizosomskog enzima i njihova upotreba
ES2583258T3 (es) Medio de cultivo celular para expresión de proteína ADAMTS
BRPI0412125A (pt) molécula de ácido nucleico isolada, polipeptìdeo de fusão, vetor de expressão, método de produzir um polipeptìdeo de fusão de vegf, captador de fator de crescimento de célula endotelial vascular, composição farmacêutica, método de tratar uma doença ou condição que são restabelecidas, melhoradas ou inibidas pela remoção ou inibição do fator de crescimento endotelial vascular, e, artigo de fabricação
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
CN104224705B (zh) 稳定化的液体和冻干的adamts13制剂
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
MX2009002816A (es) Proteinas de fusion de albumina.
CN102869679B (zh) 稳定的水性mia/cd-rap制剂
CN103097409A (zh) 在细胞培养物中生产重组高分子量vWF的方法
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
PE20151205A1 (es) Formulaciones que contienen linaclotida para administracion oral
CY1116980T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
WO2012159006A8 (en) Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
CR10591A (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol
US20150283245A1 (en) Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
FI3858375T3 (fi) Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
CA2480226A1 (en) Stable pharmaceutical composition containing factor viii
WO2005026375A3 (en) Recombinant carrier molecule for expression, delivery and purification of target polypeptides
KR101348096B1 (ko) 줄기세포의 연골 분화 유도 활성을 가지는 폴리펩타이드
MXPA02012378A (es) Secuencias de nucleotidos y aminoacidos de factores de oocito para alterar el crecimiento folicular ovarico in vivo in vitro.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2607 DE 22/12/2020.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2617, QUANTO AS REIVINDICACOES